Tirzepatide CAS 2023788-19-2
2/5/10/15mg
Tirzepatide was developed to fight type 2 diabetes, but has additionally been shown to protect the cardiovascular system and act as a potent weight loss agent. Tirzepatide is a synthetic derivative of gastric inhibitory polypeptide (GIP) that has simultaneous glucagon-like peptide-1 (GLP-1) functionality as well. This combination allows Tirzepatide to lower blood glucose levels, increase insulin sensitivity, boost feelings of satiety, and accelerate weight loss.
Semaglutide CAS 910463-68-2
2/5/10/15mg
It is a derivative of the naturally occurring GLP-1, a peptide known to lower blood sugar levels and enhance insulin secretion. Research shows that Semaglutide may also improve heart, liver, and lung function while helping to slow or prevent the effects of Alzheimer's disease. Semaglutide has been shown to significantly decrease appetite by delaying gastric emptying and reducing intestinal motility.
Retatrutide CAS 2381089-83-2
5/10/15mg
Retatrutide (LY-3437943) is under development for the treatment of type 2 diabetes mellitus, obstructive sleep apnea, osteoarthritis, obesity and non-alcoholic fatty liver disease. The drug candidate is administered through subcutaneous and intravenous route. The drug candidate acts by targeting glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. It is a new molecular entity.